Esperion Therapeutics | ESPR - Selling And Administration Expenses

Stock Price
2.77
Daily Change
0.15 5.73%
Monthly
-17.56%
Yearly
69.94%
Q1 Forecast
2.47

Esperion Therapeutics reported $39.42M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Alterity Therapeutics Limited AUD 2.29M 649.1K Jun/2023
Amarin USD 18.97M 1.03M Dec/2025
Amgen USD 1.94B 237M Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Cipla INR 13.25B 101.8M Dec/2025
CSL USD 1.23B 498M Dec/2025
Cytokinetics USD 91.72M 67.02M Dec/2025
Daiichi Sankyo JPY 228.23B 39.15B Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Esperion Therapeutics USD 39.42M 456K Dec/2025
Geron USD 41.67M 2.67M Dec/2025
Grifols EUR 320.45M 12.65M Dec/2025
Halozyme Therapeutics USD 64.64M 27.11M Dec/2025
Heron Therapeutics USD 23.74M 605K Dec/2025
Ionis Pharmaceuticals USD 130M 43.43M Dec/2025
Merck USD 2.85B 215M Dec/2025
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Moderna USD 308M 40M Dec/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Pfizer USD 4.08B 894M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
United Therapeutics USD 190.6M 38.6M Dec/2025
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024